The American Cancer Society influences cancer research across the world with knowledge that’s invaluable to the entire cancer industry. Drugs in the pipeline and treatments waiting for approval cannot be accessed by providers, payers, or patients without the contribution of surveillance and health equity research from the ACS.”
Nova Yang, MSPH, is an associate scientist in the Health Services Research team within Surveillance & Health Equity Science at the American Cancer Society (ACS).
She studies the direct and indirect effects of the COVID-19 pandemic on overall cancer care and especially on treatment.
She also studies the barriers that keep cancer survivors from using health care resources, investigating the availability and use of telehealth, insurance status, and demographic factors.
Before joining ACS, my research focused on rare diseases and orphan drug policies. I’ve noticed the huge unmet need and disease burden of rare cancer patients and their care givers. That piqued my interest in cancer drug accessibility and affordability, the economic burden among cancer patients and caregivers, and health policies aiming to bridge the gap.
I am a part-time ballet dancer.